Sean E Mcguire

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8937527/publications.pdf Version: 2024-02-01



SEAN F MCCHIPE

#	Article	IF	CITATIONS
1	Spatiotemporal Rescue of Memory Dysfunction in <i>Drosophila</i> . Science, 2003, 302, 1765-1768.	12.6	1,167
2	Spatiotemporal Gene Expression Targeting with the TARGET and Gene-Switch Systems in <i>Drosophila</i> . Science Signaling, 2004, 2004, pl6.	3.6	595
3	Gene expression systems in Drosophila: a synthesis of time and space. Trends in Genetics, 2004, 20, 384-391.	6.7	258
4	Postmastectomy Radiation Improves the Outcome of Patients With Locally Advanced Breast Cancer Who Achieve a Pathologic Complete Response to Neoadjuvant Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1004-1009.	0.8	229
5	Thirty years of olfactory learning and memory research in Drosophila melanogaster. Progress in Neurobiology, 2005, 76, 328-347.	5.7	199
6	SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Molecular Oncology, 2016, 10, 1266-1282.	4.6	151
7	Risk of Late Toxicity in Men Receiving Dose-Escalated Hypofractionated Intensity Modulated Prostate Radiation Therapy: Results From a Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1074-1084.	0.8	127
8	Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nature Metabolism, 2019, 1, 70-85.	11.9	110
9	Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nature Communications, 2013, 4, 2730.	12.8	104
10	Tumour metabolism and its unique properties in prostate adenocarcinoma. Nature Reviews Urology, 2020, 17, 214-231.	3.8	88
11	Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 2943-2949.	1.6	85
12	The miRNA Interactome in Metabolic Homeostasis. Trends in Endocrinology and Metabolism, 2015, 26, 733-745.	7.1	66
13	Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nature Communications, 2016, 7, 11612.	12.8	66
14	miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. Diabetes, 2018, 67, 2541-2553.	0.6	60
15	Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene, 2019, 38, 5700-5724.	5.9	59
16	Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2019, 104, 790-797.	0.8	56
17	Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene, 2020, 39, 6265-6285.	5.9	52
18	Don't throw the baby out with the bathwater: Enabling a bottom-up approach in genome-wide association studies: Figure 1 Genome Research, 2008, 18, 1683-1685.	5.5	49

SEAN E MCGUIRE

#	Article	IF	CITATIONS
19	Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. Cancer Cell, 2014, 26, 863-879.	16.8	46
20	Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. International Journal of Radiation Oncology Biology Physics, 2018, 100, 374-382.	0.8	42
21	The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP. Neoplasia, 2016, 18, 356-370.	5.3	40
22	Mitochondrial Activity in Human White Adipocytes Is Regulated by the Ubiquitin Carrier Protein 9/microRNA-30a Axis. Journal of Biological Chemistry, 2016, 291, 24747-24755.	3.4	30
23	PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. International Journal of Radiation Oncology Biology Physics, 2013, 85, e39-e46.	0.8	24
24	Quality of life after brachytherapy or bilateral nerveâ€sparing robotâ€essisted radical prostatectomy for prostate cancer: a prospective cohort. BJU International, 2018, 121, 540-548.	2.5	22
25	Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Advances in Radiation Oncology, 2017, 2, 249-258.	1.2	21
26	Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer, 2020, 126, 506-514.	4.1	21
27	Prostate Cancer Energetics and Biosynthesis. Advances in Experimental Medicine and Biology, 2019, 1210, 185-237.	1.6	19
28	Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Network Open, 2020, 3, e201255.	5.9	18
29	Local recurrence map to guide target volume delineation after radical prostatectomy. Practical Radiation Oncology, 2014, 4, e239-e246.	2.1	16
30	Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial. International Journal of Particle Therapy, 2016, 3, 27-36.	1.8	14
31	Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy, 2020, 19, 574-583.	0.5	13
32	Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. Molecular Endocrinology, 2015, 29, 1320-1333.	3.7	10
33	Treatment of recurrent vaginal melanoma with external beam radiation therapy and palladium-103 brachytherapy. Brachytherapy, 2008, 7, 359-363.	0.5	9
34	Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Practical Radiation Oncology, 2012, 2, e7-e13.	2.1	8
35	Deciphering Genomic Risk in Prostate Cancer—Ready for Prime Time. JAMA Oncology, 2021, 7, 553.	7.1	2
36	DNA Damage and Repair Pathway Profiles as Biomarkers in High-Risk Prostate Cancer. JAMA Oncology, 2016, 2, 480.	7.1	1

#	Article	IF	CITATIONS
37	Outcomes after adjuvant radiation therapy for prostate cancer at a comprehensive cancer center. Journal of Radiation Oncology, 2016, 5, 287-292.	0.7	0
38	Effect of adding short-term androgen deprivation therapy to dose-escalated radiation therapy on failure-free survival for select men with intermediate-risk prostate cancer Journal of Clinical Oncology, 2012, 30, 176-176.	1.6	0